Idexx Laboratories, Inc (NASDAQ: IDXX) kicked off on Tuesday, down -0.83% from the previous trading day, before settling in for the closing price of $419.83. Over the past 52 weeks, IDXX has traded in a range of $404.74-$583.39.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 10.69%. While this was happening, its average annual earnings per share was recorded 3.88%. With a float of $81.08 million, this company’s outstanding shares have now reached $83.03 million.
Let’s determine the extent of company efficiency that accounts for 11000 employees. In terms of profitability, gross margin is 60.72%, operating margin of 28.97%, and the pretax margin is 28.43%.
Idexx Laboratories, Inc (IDXX) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Diagnostics & Research Industry. The insider ownership of Idexx Laboratories, Inc is 0.99%, while institutional ownership is 91.18%. The most recent insider transaction that took place on Sep 06 ’24, was worth 234,686. In this transaction Director of this company sold 500 shares at a rate of $469.37, taking the stock ownership to the 0 shares. Before that another transaction happened on Sep 06 ’24, when Company’s Director proposed sale 500 for $469.78, making the entire transaction worth $234,890.
Idexx Laboratories, Inc (IDXX) Earnings and Forecasts
In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported 2.32 earnings per share (EPS), higher than consensus estimate (set at 2.12) by 0.2. Wall Street market experts anticipate that the next fiscal year will bring earnings of 3.03 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 3.88% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 13.00% during the next five years compared to 18.76% growth over the previous five years of trading.
Idexx Laboratories, Inc (NASDAQ: IDXX) Trading Performance Indicators
Take a look at Idexx Laboratories, Inc’s (IDXX) current performance indicators. Last quarter, stock had a quick ratio of 0.98. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 8.87. Likewise, its price to free cash flow for the trailing twelve months is 43.01.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 10.36, a number that is poised to hit 2.39 in the next quarter and is forecasted to reach 11.96 in one year’s time.
Technical Analysis of Idexx Laboratories, Inc (IDXX)
Looking closely at Idexx Laboratories, Inc (NASDAQ: IDXX), its last 5-days average volume was 0.61 million, which is a jump from its year-to-date volume of 0.5 million. As of the previous 9 days, the stock’s Stochastic %D was 28.08%. Additionally, its Average True Range was 11.07.
During the past 100 days, Idexx Laboratories, Inc’s (IDXX) raw stochastic average was set at 9.22%, which indicates a significant decrease from 28.93% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 47.90% in the past 14 days, which was higher than the 28.38% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $465.52, while its 200-day Moving Average is $497.16. However, in the short run, Idexx Laboratories, Inc’s stock first resistance to watch stands at $420.75. Second resistance stands at $425.16. The third major resistance level sits at $428.36. If the price goes on to break the first support level at $413.14, it is likely to go to the next support level at $409.94. Should the price break the second support level, the third support level stands at $405.53.
Idexx Laboratories, Inc (NASDAQ: IDXX) Key Stats
The company with the Market Capitalisation of 34.09 billion has total of 81,885K Shares Outstanding. Its annual sales at the moment are 3,661 M in contrast with the sum of 845,040 K annual income. Company’s last quarter sales were recorded 975,540 K and last quarter income was 232,840 K.
